SHIFTBIO is proud to announce the publication of our latest research on our Inflammation-targeted Natural Nanoparticle (I-NNP) platform, SIRP-NNP, in the prestigious journal Kidney International. This milestone highlights our platform’s potential to redefine the treatment of Acute Kidney Injury, a condition currently lacking disease-specific therapies.
By introducing engineered SIRP-NNP, we have established a novel therapeutic approach that specifically targets CD47-overexpressing myeloid cells within the bloodstream. Unlike traditional tissue-specific delivery, our strategy focuses on therapeutic reprogramming at the systemic level. By modulating the CD47-SIRP interaction, we intercept and transform circulating immune cells into pro-resolving phenotypes before they can infiltrate and damage organ tissues. This NNP-based strategy actively promotes tissue repair while providing a scalable and safer alternative to conventional cell-based therapies, presenting a promising path for clinical translation and large-scale manufacturing.
In addition to therapeutic efficacy, our study highlights the potential of urinary CD47 as a non-invasive biomarker. This discovery offers a new tool for early detection and real-time monitoring of kidney injury.
We invite our partners and the scientific community to explore how SHIFTBIO is leveraging advanced NNP engineering to lead the next wave of treatments for inflammatory diseases!
For more information: https://www.kidney-international.org/article/S0085-2538(25)01022-1/abstract
SHIFTBIO is proud to announce the publication of our latest research on our Inflammation-targeted Natural Nanoparticle (I-NNP) platform, SIRP-NNP, in the prestigious journal Kidney International. This milestone highlights our platform’s potential to redefine the treatment of Acute Kidney Injury, a condition currently lacking disease-specific therapies.
By introducing engineered SIRP-NNP, we have established a novel therapeutic approach that specifically targets CD47-overexpressing myeloid cells within the bloodstream. Unlike traditional tissue-specific delivery, our strategy focuses on therapeutic reprogramming at the systemic level. By modulating the CD47-SIRP interaction, we intercept and transform circulating immune cells into pro-resolving phenotypes before they can infiltrate and damage organ tissues. This NNP-based strategy actively promotes tissue repair while providing a scalable and safer alternative to conventional cell-based therapies, presenting a promising path for clinical translation and large-scale manufacturing.
In addition to therapeutic efficacy, our study highlights the potential of urinary CD47 as a non-invasive biomarker. This discovery offers a new tool for early detection and real-time monitoring of kidney injury.
We invite our partners and the scientific community to explore how SHIFTBIO is leveraging advanced NNP engineering to lead the next wave of treatments for inflammatory diseases!
For more information: https://www.kidney-international.org/article/S0085-2538(25)01022-1/abstract